Esperion Therapeutics ESPR Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's change in deferred revenue?
- Esperion Therapeutics (ESPR) reported change in deferred revenue of $9.05M in Q1 2026.
- How has Esperion Therapeutics's change in deferred revenue changed year-over-year?
- Esperion Therapeutics's change in deferred revenue increased by 327.7% year-over-year, from -$3.98M to $9.05M.
- What is the long-term trend for Esperion Therapeutics's change in deferred revenue?
- Over 2 years (2023 to 2025), Esperion Therapeutics's change in deferred revenue has grown at a 8.9% compound annual growth rate (CAGR), from $21.9M to $25.96M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.